Patients with COVID-19 more often received saturating doses of acetylsalicylic acid, unfractionated heparin (UFH), low molecular weight heparin (LMWH), strong P2Y12 inhibitors, and GPI IIb/IIIa inhibitors. This evidence concerns the gene P2RY12 and COVID-19.